Laboratorios Sophia S.A de C.V.   Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Zapopan Mexico (1946)
Status: No NME R&D (1946)

Organization Overview

First Clinical Trial
2006
NCT01062971
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Clinical Research Department. Laboratorios Sophia SA de CV | Laboratorios Sophia S.A de C.V.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cataract (Phase 3)

Conjunctivitis (Phase 3)

Conjunctivitis, Allergic (Phase 3)

Conjunctivitis, Bacterial (Phase 3)

Dry Eye Syndromes (Phase 4)

Glaucoma (Phase 3)

Glaucoma, Open-Angle (Phase 3)

Hypertension (Phase 3)

Inflammation (Phase 4)

Keratoconjunctivitis Sicca (Phase 3)

Ocular Hypertension (Phase 3)

Pterygium (Phase 4)

Syndrome (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 34
  • # of Trial APIs: 35